Jpmorgan Chase & CO Aquestive Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 75,500 shares of AQST stock, worth $258,210. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,500
Previous 45,033
67.65%
Holding current value
$258,210
Previous $224,000
19.2%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AQST
# of Institutions
122Shares Held
47.1MCall Options Held
517KPut Options Held
207K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$33.6 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$19 Million2.87% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$18.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$14.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.13MShares$7.3 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $182M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...